GUMDROP : A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of ARQ 197 (tivatinib) in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Created by Nancy Dawson, last modified on May 28, 2012

Description:

The purpose of this study is to assess the improvement in progression-free survival in men with castrate-resistant prostate cancer who are minimally symptomatic or asymptomatic, treated with ARQ 197 versus placebo

Link:

ARQ197 prostate cancer

Site:

Georgetown University Hospital

Principal Investigator:

Dr. Nancy Dawson